#
Nelarabine Injection
  • Professionals
  • FDA PI

Nelarabine Injection

Dosage form: injection
Drug class:Antimetabolites

Medically reviewed by Drugs.com. Last updated on Nov 1, 2021.

WARNING: NEUROLOGIC ADVERSE REACTIONS

Severe neurologic adverse reactions have been reported with the use of nelarabine. These adverse reactions have included altered mental states including severe somnolence, central nervous system effects including convulsions, and peripheral neuropathy ranging from numbness and paresthesias to motor weakness and paralysis. There have also been reports of adverse reactions associated with demyelination, and ascending peripheral neuropathies similar in appearance to Guillain-Barr¡SR syndrome [see Warnings and Precautions (5.1)].

Full recovery from these adverse reactions has not always occurred with cessation of therapy with nelarabine. Monitor frequently for signs and symptoms of neurologic toxicity during treatment with nelarabine. Discontinue nelarabine for neurologic adverse reactions of NCI Common Toxicity Criteria for Adverse Events (CTCAE) Grade 2 or greater [see Warnings and Precautions (5.1)].

1. INDICATIONS AND USAGE

Nelarabine Injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.

2. DOSAGE AND ADMINISTRATION

Recommended Dosage

This product is for intravenous use only.

Adult Dosage: The recommended adult dose of Nelarabine Injection is 1,500 mg/m administered intravenously over 2 hours on Days 1, 3, and 5 repeated every 21 days. ...